Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction
Aim. To study the dynamics of procollagen type I carboxy-terminal propeptide (PICP) with an assessment of potential associations with cardiac fibrosis (CF) and diastolic dysfunction (DD) of the left ventricle (LV) during the hospitalization and one year after ST segment elevation myocardial infarcti...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-03-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4137 |
| _version_ | 1797856661742813184 |
|---|---|
| author | A. V. Osokina V. N. Karetnikova O. M. Polikutina A. V. Ivanova T. B. Pecherina O. V. Gruzdeva Yu. A. Dyleva A. N. Kokov N. K. Brel O. L. Barbarash |
| author_facet | A. V. Osokina V. N. Karetnikova O. M. Polikutina A. V. Ivanova T. B. Pecherina O. V. Gruzdeva Yu. A. Dyleva A. N. Kokov N. K. Brel O. L. Barbarash |
| author_sort | A. V. Osokina |
| collection | DOAJ |
| description | Aim. To study the dynamics of procollagen type I carboxy-terminal propeptide (PICP) with an assessment of potential associations with cardiac fibrosis (CF) and diastolic dysfunction (DD) of the left ventricle (LV) during the hospitalization and one year after ST segment elevation myocardial infarction (STEMI).Material and methods. The study included 120 patients with STEMI. There were following inclusion criteria: diagnosis of STEMI (2015 European Society of Cardiology guidelines); Killip £III acute heart failure (AHF); signed informed consent; patient age >18 years old. There were following exclusion criteria: STEMI due to percutaneous coronary intervention or coronary artery bypass grafting; Killip IV AHF; patient age >80 years; clinically significant comorbidities; death of the patient during the first day of hospitalization. On the 1st, 12th day of the disease and after a year all patients underwent echocardiography and the PICP concentration was determined. One year after myocardial infarction, contrast-enhanced cardiac magnetic resonance imaging was performed to assess CF. In the analyzed group of patients, on day 1 of STEMI, mean values of LV ejection fraction (EF) in the range of 40-49% were observed in 3 (2,5%) patients, LVEF <40% — in 31 (26%), LVEF ≥50% — in 86 (71,7%). The final analysis was performed on a sample of patients with preserved LVEF (n=86) (71,7%).Results. On the first day of myocardial infarction, signs of DD were noted in 25 (29,1%) patients, while after 1 year, their number increased by 9 (10%) and amounted to 34 (39,5%) patients. In 15 (17,6%) people, worsening of myocardial systolic dysfunction was noted. Patients with a CF ³16% had the highest PICP expression on the first day of the disease. CF ≥16% one year after STEMI with preserved EF is associated with PICP concentration on day 1 of the disease. In addition, multidirectional correlations were revealed between the CF ≥16% and parameters of LV diastolic function (e’, mean pulmonary artery pressure, E/e’).Conclusion. Determination of the PICP concentration on the 1st day of myocardial infarction will allow early identification of patients at risk of CF one year after STEMI with preserved EF. |
| first_indexed | 2024-04-09T20:44:05Z |
| format | Article |
| id | doaj.art-0efbac89892c42c4a3c486523ce450a9 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:44:05Z |
| publishDate | 2021-03-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-0efbac89892c42c4a3c486523ce450a92023-03-29T21:23:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202021-03-0126210.15829/1560-4071-2021-41373131Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fractionA. V. Osokina0V. N. Karetnikova1O. M. Polikutina2A. V. Ivanova3T. B. Pecherina4O. V. Gruzdeva5Yu. A. Dyleva6A. N. Kokov7N. K. Brel8O. L. Barbarash9Research Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesAim. To study the dynamics of procollagen type I carboxy-terminal propeptide (PICP) with an assessment of potential associations with cardiac fibrosis (CF) and diastolic dysfunction (DD) of the left ventricle (LV) during the hospitalization and one year after ST segment elevation myocardial infarction (STEMI).Material and methods. The study included 120 patients with STEMI. There were following inclusion criteria: diagnosis of STEMI (2015 European Society of Cardiology guidelines); Killip £III acute heart failure (AHF); signed informed consent; patient age >18 years old. There were following exclusion criteria: STEMI due to percutaneous coronary intervention or coronary artery bypass grafting; Killip IV AHF; patient age >80 years; clinically significant comorbidities; death of the patient during the first day of hospitalization. On the 1st, 12th day of the disease and after a year all patients underwent echocardiography and the PICP concentration was determined. One year after myocardial infarction, contrast-enhanced cardiac magnetic resonance imaging was performed to assess CF. In the analyzed group of patients, on day 1 of STEMI, mean values of LV ejection fraction (EF) in the range of 40-49% were observed in 3 (2,5%) patients, LVEF <40% — in 31 (26%), LVEF ≥50% — in 86 (71,7%). The final analysis was performed on a sample of patients with preserved LVEF (n=86) (71,7%).Results. On the first day of myocardial infarction, signs of DD were noted in 25 (29,1%) patients, while after 1 year, their number increased by 9 (10%) and amounted to 34 (39,5%) patients. In 15 (17,6%) people, worsening of myocardial systolic dysfunction was noted. Patients with a CF ³16% had the highest PICP expression on the first day of the disease. CF ≥16% one year after STEMI with preserved EF is associated with PICP concentration on day 1 of the disease. In addition, multidirectional correlations were revealed between the CF ≥16% and parameters of LV diastolic function (e’, mean pulmonary artery pressure, E/e’).Conclusion. Determination of the PICP concentration on the 1st day of myocardial infarction will allow early identification of patients at risk of CF one year after STEMI with preserved EF.https://russjcardiol.elpub.ru/jour/article/view/4137myocardial infarctiondiastolic dysfunctionchronic heart failurecardiofibrosisserum markers of fibrosis |
| spellingShingle | A. V. Osokina V. N. Karetnikova O. M. Polikutina A. V. Ivanova T. B. Pecherina O. V. Gruzdeva Yu. A. Dyleva A. N. Kokov N. K. Brel O. L. Barbarash Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction Российский кардиологический журнал myocardial infarction diastolic dysfunction chronic heart failure cardiofibrosis serum markers of fibrosis |
| title | Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction |
| title_full | Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction |
| title_fullStr | Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction |
| title_full_unstemmed | Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction |
| title_short | Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction |
| title_sort | participation of the c terminal propeptide procollagen type i in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction |
| topic | myocardial infarction diastolic dysfunction chronic heart failure cardiofibrosis serum markers of fibrosis |
| url | https://russjcardiol.elpub.ru/jour/article/view/4137 |
| work_keys_str_mv | AT avosokina participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT vnkaretnikova participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT ompolikutina participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT avivanova participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT tbpecherina participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT ovgruzdeva participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT yuadyleva participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT ankokov participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT nkbrel participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction AT olbarbarash participationofthecterminalpropeptideprocollagentypeiintheformationofcardiofibrosisinpatientswithmyocardialinfarctionwithpreservedleftventricularejectionfraction |